ARYx currently has four proprietary drug candidates in the clinic and additional leads undergoing optimization. While our technologies can be applied to oral drugs, topical agents and injectables for a wide variety of disease indications, our initial candidates are oral drugs aimed at large, chronic markets. Our current clinical compounds are:

ATI-7505 Gastrointestinal Disorders
ATI-2042 Atrial Fibrillation
ATI-5923 Anticoagulation
ATI-9242 Psychiatric Disorders

ATI-7505 - Gastrointestinal Disorders

ATI-7505 is a proprietary serotonin type 4 (5HT4) agonist in Phase 2 development for the treatment of multiple gastrointestinal disorders. Potential indications include chronic constipation, functional dyspepsia, gastroesophageal reflux disease (GERD), gastroparesis (delayed emptying of the stomach), and inflammatory bowel disease with constipation. Each of these indications addresses significant patient populations. The efficacy of 5HT4 agonists in gastrointestinal disorders is well established, although serious cardiac liabilities have significantly limited their use. ATI-7505 is designed to provide prokinetic activity in the gastrointestinal tract without cardiac safety problems at anticipated therapeutic doeses.

In June 2006, we entered into a collaboration agreement with Procter & Gamble Pharmaceuticals under which P&G will develop and commercialize ATI-7505 for treatment of gastrointestinal disorders. ARYx retains rights to co-develop and co-promote the drug.

ATI-2042 - Atrial Fibrillation

ATI-2042 is a proprietary compound in Phase 2 development for the treatment of atrial fibrillation (AFIB). ARYx has engineered ATI-2042 with the goal of developing a therapy equally effective but safer than amiodarone, considered by physicians to be the most effective drug for treating patients with atrial fibrillation. Although amiodarone is not approved for treatment of atrial fibrillation, it remains the market leader. Treatment of AFIB with amiodarone has been severely limited by the toxic side effects resulting from accumulation of the drug. ATI-2042 is designed to preserve the effective pharmacology of amiodarone while mitigating the safety issues.

ATI-5923 - Anticoagulation

ATI-5923, a novel compound for oral anti-coagulation therapy, is currently in Phase 2 clinical trials. ARYx has designed ATI-5923 to preserve the efficacy and complex pharmacology of Coumadin® (warfarin), the current market leader, while improving the safety profile. Like warfarin, ATI-5923 depletes certain clotting proteins in the blood, thereby reducing the occurrence of deep vein thrombosis (DVT) and the risk of stroke associated with atrial fibrillation (AFIB). ATI-5923 is metabolized by non-oxidative enzymes to a single inactive entity and thus far appears to have less variable metabolism and reduced instances of under/over anticoagulation, making the response to ATI-5923 safer and more predictable.

ATI-9242 - Psychiatric Disorders

ATI-9242 is designed to be a novel, next-generation atypical antipsychotic for the treatment of schizophrenia and other psychiatric disorders. We believe this product will improve upon the efficacy of the best atypicals while avoiding metabolic drug-drug interactions and minimizing certain other metabolic problems associated with atypicals, including weight gain and type 2 diabetes. The receptor profile of ATI-9242 is designed to treat negative symptoms of schizophrenia - reduction in social interaction, disassociation from people or settings, monotone speech, loss of feelings of pleasure - and enhance cognitive functions. We entered the clinic with ATI-9242 in April 2008.

More Information

For more information about our products and partnering opportunities, please contact ARYx.